Cullinan Management, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from BTIG maintained a Buy rating on the stock and has a $32.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison has given his Buy rating due to a combination of factors that highlight the potential of Cullinan Management’s zipalertinib in treating non-small cell lung cancer (NSCLC) with uncommon EGFR mutations. The preliminary results from the Phase 2b REZILIENT2 trial demonstrate a 30% overall response rate (ORR) and a 70% disease control rate (DCR) in patients with uncommon non-ex20ins EGFR mutations, which is promising for expanding the treatment’s target market.
The data also shows that treatment-naive patients exhibited a significantly higher ORR of 62.5% compared to those with prior treatments, suggesting zipalertinib’s effectiveness in earlier treatment settings. The safety profile of zipalertinib remains consistent with previous studies, and the anticipation of further data from ongoing trials supports the potential for broader application. These factors contribute to the positive outlook and the Buy rating for Cullinan Management’s stock.